MetaStat Akcija

MetaStat AAQS

Vrijednost AAQS od MetaStat (MTST) na dan 9. авг 2026. je 4. Prethodne godine, AAQS je bio 4,00 — promjena od 0,00% (niži).

AAQS

4

YoY

0,00%

Zadnja ažuriranja:

MetaStat ima trenutni AAQS od 4. Visok AAQS može se smatrati pozitivnim pokazateljem da se preduzeće uspešno razvija. Investitori mogu očekivati da je kompanija na dobrom putu da ostvari dobit. S druge strane, važno je posmatrati AAQS deonice MetaStat u poređenju sa ostvarenom dobiti i drugim preduzećima iste branše. Visok AAQS nije apsolutna garancija za pozitivnu budućnost. Samo tako se može dobiti kompletna slika o performansama kompanije. Da bi se bolje procenio razvoj preduzeća, važno je posmatrati AAQS u poređenju sa drugim kompanijama iste branše. Generalno, investitori bi uvek trebali da posmatraju AAQS kompanije u kontekstu sa drugim finansijskim pokazateljima kao što su dobit, EBIT, Cash Flow i drugi, kako bi doneli obrazovane odluke o investiranju.
Access this data via the Eulerpool API

MetaStat Анализа акција

Šta radi MetaStat? MetaStat Inc. is a biopharmaceutical company focused on the development of therapeutics for cancer. It was founded in Massachusetts in 2000 and has been listed on NASDAQ since 2013. The company's main focus is on blocking the protein Meta-1, which is associated with the formation of metastases, in order to stop the spread of cancer. MetaStat's business model is based on marketing medications and diagnostics. They work closely with researchers and clinicians to develop new products and conduct clinical trials. The company operates in two divisions: therapeutics and diagnostics. The therapeutics division focuses on developing medications targeting the Meta-1 protein, while the diagnostics division develops tests to detect Meta-1 protein in patients' blood to identify metastases early on. MetaStat's main product is the MetaSite Breast Test, a diagnostic test for breast cancer that uses proprietary technologies to detect the presence of Meta-1 in tumor tissue. The company also has several therapeutics in the pipeline, with MSC-1, a small molecule that blocks the function of Meta-1 and inhibits the formation of metastases, being the leading product. MetaStat has established partnerships with several research institutions and companies to advance its research and development. In summary, MetaStat is a biopharmaceutical company specializing in the development of therapeutics and diagnostics for cancer. They have developed innovative technology to detect the presence of Meta-1 in tumor tissue and inhibit the formation of metastases. Their main product is the MetaSite Breast Test, which determines the risk of metastases in breast cancer patients. The company has established partnerships with research institutions and companies to advance its research and development and further develop its pipeline of therapeutics. MetaStat je jedna od najpopularnijih kompanija na Eulerpool.

Često postavljena pitanja o akciji MetaStat

AAQS kompanije MetaStat iznosi 4 u 2026. godini.

Na Eulerpool-u možete pronaći potpuni historijski razvoj AAQS MetaStat od 2006. — sa godišnjim vrijednostima, grafikonima i detaljnom analizom.

AAQS je pokazatelj koji je razvila kompanija AlleAktien.

AAQS je pokazatelj koji je razvila kompanija AlleAktien.

Access this data via the Eulerpool API

Квалитет — MetaStat

Sve ključne metrike — MetaStat

Раст